Welcome to LookChem.com Sign In|Join Free

CAS

  • or
8-Bromoquinazoline-2,4(1H,3H)-dione is a quinazoline derivative with the molecular formula C8H5BrN2O2. It features a bromine atom at the 8-position and carbonyl groups at the 2 and 4 positions. This chemical compound has been investigated for its potential biological activities, such as its anticancer properties and enzyme inhibitory effects. Additionally, it has been considered as a building block in the synthesis of more complex organic compounds, making it a versatile chemical with applications in both the pharmaceutical and chemical industries.

331646-99-2 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 331646-99-2 Structure
  • Basic information

    1. Product Name: 8-bromoquinazoline-2,4(1H,3H)-dione
    2. Synonyms: 8-bromoquinazoline-2,4(1H,3H)-dione;8-Bromo-2,4(1H,3H)-quinazolinedione;2,4(1H,3H)-Quinazolinedione, 8-bromo-;8-Bromo-1H-quinazoline-2,4-dione;8-BROMO-2,4-DIHYDROXY QUINOZALINE
    3. CAS NO:331646-99-2
    4. Molecular Formula: C8H5BrN2O2
    5. Molecular Weight: 241.0415
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 331646-99-2.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: 537.6 °C at 760 mmHg
    3. Flash Point: 278.9 °C
    4. Appearance: /
    5. Density: 1.959 g/cm3
    6. Vapor Pressure: 3.58E-12mmHg at 25°C
    7. Refractive Index: 1.782
    8. Storage Temp.: Sealed in dry,Room Temperature
    9. Solubility: N/A
    10. PKA: 10.29±0.20(Predicted)
    11. CAS DataBase Reference: 8-bromoquinazoline-2,4(1H,3H)-dione(CAS DataBase Reference)
    12. NIST Chemistry Reference: 8-bromoquinazoline-2,4(1H,3H)-dione(331646-99-2)
    13. EPA Substance Registry System: 8-bromoquinazoline-2,4(1H,3H)-dione(331646-99-2)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 331646-99-2(Hazardous Substances Data)

331646-99-2 Usage

Uses

Used in Pharmaceutical Industry:
8-Bromoquinazoline-2,4(1H,3H)-dione is used as an anticancer agent for its potential to target and inhibit the growth of cancer cells. Its biological activities have been studied, and it has shown promise in the development of treatments for various types of cancer.
Used in Chemical Industry:
8-Bromoquinazoline-2,4(1H,3H)-dione serves as a building block in the synthesis of more complex organic compounds. Its unique structure and functional groups make it a valuable component in the creation of new molecules with specific properties and applications in various chemical processes.
Used in Enzyme Inhibition:
8-Bromoquinazoline-2,4(1H,3H)-dione is used as an enzyme inhibitor, targeting specific enzymes involved in various biological processes. Its inhibitory effects have potential applications in the development of drugs for treating enzyme-related diseases and conditions.

Check Digit Verification of cas no

The CAS Registry Mumber 331646-99-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,3,1,6,4 and 6 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 331646-99:
(8*3)+(7*3)+(6*1)+(5*6)+(4*4)+(3*6)+(2*9)+(1*9)=142
142 % 10 = 2
So 331646-99-2 is a valid CAS Registry Number.
InChI:InChI=1/C8H5BrN2O2/c9-5-3-1-2-4-6(5)10-8(13)11-7(4)12/h1-3H,(H2,10,11,12,13)

331646-99-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 20, 2017

Revision Date: Aug 20, 2017

1.Identification

1.1 GHS Product identifier

Product name 8-bromo-1H-quinazoline-2,4-dione

1.2 Other means of identification

Product number -
Other names 8-bromoquinazoline-2,4(1H,3H)-dione

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:331646-99-2 SDS

331646-99-2Relevant articles and documents

Discovery of (R)-8-(6-Methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4- b]pyrrol-2-yl)-3-(1-methylcyclopropyl)-2-((1-methylcyclopropyl)amino)quinazolin-4(3 H)-one, a Potent and Selective Pim-1/2 Kinase Inhibitor for Hematological Malignancies

Wang, Hui-Ling,Andrews, Kristin L.,Booker, Shon K.,Canon, Jude,Cee, Victor J.,Chavez, Frank,Chen, Yuping,Eastwood, Heather,Guerrero, Nadia,Herberich, Brad,Hickman, Dean,Lanman, Brian A.,Laszlo, Jimmy,Lee, Matthew R.,Lipford, J. Russell,Mattson, Bethany,Mohr, Christopher,Nguyen, Yen,Norman, Mark H.,Pettus, Liping H.,Powers, David,Reed, Anthony B.,Rex, Karen,Sastri, Christine,Tamayo, Nuria,Wang, Paul,Winston, Jeffrey T.,Wu, Bin,Wu, Qiong,Wu, Tian,Wurz, Ryan P.,Xu, Yang,Zhou, Yihong,Tasker, Andrew S.

, p. 1523 - 1540 (2019)

Pim kinases are a family of constitutively active serine/threonine kinases that are partially redundant and regulate multiple pathways important for cell growth and survival. In human disease, high expression of the three Pim isoforms has been implicated in the progression of hematopoietic and solid tumor cancers, which suggests that Pim kinase inhibitors could provide patients with therapeutic benefit. Herein, we describe the structure-guided optimization of a series of quinazolinone-pyrrolodihydropyrrolone analogs leading to the identification of potent pan-Pim inhibitor 28 with improved potency, solubility, and drug-like properties. Compound 28 demonstrated on-target Pim activity in an in vivo pharmacodynamic assay with significant inhibition of BAD phosphorylation in KMS-12-BM multiple myeloma tumors for 16 h postdose. In a 2-week mouse xenograft model, daily dosing of compound 28 resulted in 33% tumor regression at 100 mg/kg.

COMPOUND FOR ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME

-

, (2020/08/05)

The present invention discloses an organic compound and an organic electroluminescence device using the organic compound as a material in the light emitting layer of the organic electroluminescence device. The organic compound may be for lowering a driving voltage, power consumption or increasing a current efficiency or 90% life time of the organic electroluminescence device. The same definition as described in the present invention.

Discovery of Quinazolines That Activate SOS1-Mediated Nucleotide Exchange on RAS

Abbott, Jason R.,Patel, Pratiq A.,Howes, Jennifer E.,Akan, Denis T.,Kennedy, J. Phillip,Burns, Michael C.,Browning, Carrie F.,Sun, Qi,Rossanese, Olivia W.,Phan, Jason,Waterson, Alex G.,Fesik, Stephen W.

supporting information, p. 941 - 946 (2018/09/06)

Proteins in the RAS family are important regulators of cellular signaling and, when mutated, can drive cancer pathogenesis. Despite considerable effort over the last 30 years, RAS proteins have proven to be recalcitrant therapeutic targets. One approach for modulating RAS signaling is to target proteins that interact with RAS, such as the guanine nucleotide exchange factor (GEF) son of sevenless homologue 1 (SOS1). Here, we report hit-to-lead studies on quinazoline-containing compounds that bind to SOS1 and activate nucleotide exchange on RAS. Using structure-based design, we refined the substituents attached to the quinazoline nucleus and built in additional interactions not present in the initial HTS hit. Optimized compounds activate nucleotide exchange at single-digit micromolar concentrations in vitro. In HeLa cells, these quinazolines increase the levels of RAS-GTP and cause signaling changes in the mitogen-activated protein kinase/extracellular regulated kinase (MAPK/ERK) pathway.

QUINAZOLINE COMPOUNDS AS MODULATORS OF RAS SIGNALING

-

Page/Page column 70, (2018/12/13)

The present invention relates to quinazoline compounds and compositions that modulate Ras signaling. Compounds and compositions of the present invention are useful in the treatment of cancers and other disease states associated with Ras dysfunction (e.g.,

CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF

-

Paragraph 0191; 0192, (2018/03/25)

Disclosed are a condensed-ring pyrimidylamino derivative, a preparation method therefor, and an intermediate, a pharmaceutical composition and applications thereof. The method for preparing the condensed-ring pyrimidylamino derivative comprises: in a solvent, in the presence of a palladium-containing catalyst, allowing a compound represented by formula I-a and a compound represented by formula I-b' to have a coupling reaction, and then preparing a compound represented by formula I by means of a deprotection reaction. Also disclosed applications of the condensed-ring pyrimidylamino derivative in the preparation of drugs for preventing, relieving and/or treating tumors or diseases caused by an anaplastic lymphoma kinase. The condensed-ring pyrimidylamino derivative of the present invention has an obvious restraint effect on the anaplastic lymphoma kinase.

FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF

-

Paragraph 0478-0479, (2018/08/12)

Disclosed area fused ring pyrimidine compound, and an intermediate, a preparation method, a composition and a use thereof. The fused ring pyrimidine compound is a compound as shown in formula I, a tautomer, an enantiomer, a diastereoisomer, a pharmaceutically acceptable salt, a metabolite, a metabolic precursor or a prodrug thereof, wherein the above-mentioned compound is used for the preparation of a medicine for preventing, remitting or treating one or more of immune system diseases, autoimmune diseases, cell proliferative diseases, allergic disorders and cardiovascular diseases, and the compound has a strong inhibitory effect on the Janues kinase, FGFR kinase, FLT3 kinase and Src family kinase.

Discovery of 5-Phenyl-N-(pyridin-2-ylmethyl)-2-(pyrimidin-5-yl)quinazolin-4-amine as a Potent IKur Inhibitor

Finlay, Heather J.,Johnson, James A.,Lloyd, John L.,Jiang, Ji,Neels, James,Gunaga, Prashantha,Banerjee, Abhisek,Dhondi, Naveen,Chimalakonda, Anjaneya,Mandlekar, Sandhya,Conder, Mary Lee,Sale, Harinath,Xing, Dezhi,Levesque, Paul,Wexler, Ruth R.

, p. 831 - 834 (2016/10/12)

A new series of phenylquinazoline inhibitors of Kv 1.5 is disclosed. The series was optimized for Kv 1.5 potency, selectivity versus hERG, pharmacokinetic exposure, and pharmacodynamic potency. 5-Phenyl-N-(pyridin-2-ylmethyl)-2-(pyrimidin-5-yl)quinazolin-4-amine (13k) was identified as a potent and ion channel selective inhibitor with robust efficacy in the preclinical rat ventricular effective refractory period (VERP) model and the rabbit atrial effective refractory period (AERP) model.

CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS

-

Paragraph 0286, (2016/09/15)

Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.

CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS

-

Paragraph 0213, (2015/03/13)

Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.

The components of xRNA: Synthesis and fluorescence of a full genetic set of size-expanded ribonucleosides

Hernandez, Armando R.,Kool, Eric T.

, p. 676 - 679 (2011/05/03)

The synthesis and properties of a full set of four benzo-expanded ribonucleosides (xRNA), analogous to A, G, C, and U RNA monomers, are described. The nucleosides are efficient fluorophores with emission maxima of 369-411 nm. The compounds are expected to

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 331646-99-2